Elliott D. Kieff

Q: What Schools Are Affiliated With Elliott D. Kieff

Elliott D. Kieff is affiliated with the following schools: Harvard University, University of Pennsylvania, Weizmann Institute of Science, Paris Sciences et Lettres University, University of Tokyo, University of Chicago, Thomas Jefferson University, Washington University in St. Louis, University of Birmingham, University of North Carolina at Chapel Hill

Elliott D. Kieff's AcademicInfluence.com Rankings

Elliott D. Kieff

Biology

#3775

World Rank

#5725

Historical Rank

#1502

USA Rank

Virology

#64

World Rank

#67

Historical Rank

#25

USA Rank

Molecular Biology

#311

World Rank

#316

Historical Rank

#120

USA Rank

biology Degrees

Download Badge

Biology

Why Is Elliott D. Kieff Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Elliott D. Kieff is an American physician who is the emeritus Harriett Ryan Albee Professor of Microbiology and Immunobiology at Harvard Medical School and Brigham and Women’s Hospital. He had previously served as Chair of the Virology Program at Harvard Medical School from 1991 to 2004.

(See a Problem?)

Elliott D. Kieff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Epstein-Barr virus and its replication (1996) (1983)
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells (1985) (1295)
Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death (1991) (1236)
Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. (1968) (850)
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. (1989) (813)
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. (1993) (805)
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 (1990) (604)
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies (1992) (557)
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation (1996) (526)
Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation (1994) (524)
Identification of TRAF6, a Novel Tumor Necrosis Factor Receptor-associated Factor Protein That Mediates Signaling from an Amino-terminal Domain of the CD40 Cytoplasmic Region* (1996) (519)
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. (1989) (514)
Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis (1987) (491)
Epstein-barr virus-induced posttransplant lymphoproliferative disorders (1999) (475)
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes (1990) (472)
A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. (1999) (440)
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation (1993) (435)
Proteins of purified Epstein-Barr virus. (2004) (423)
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development (1992) (414)
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity (1988) (405)
Epstein–Barr virus and virus human protein interaction maps (2007) (398)
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. (1994) (395)
The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB (1997) (388)
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. (1987) (383)
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. (1995) (349)
Size, Composition, and Structure of the Deoxyribonucleic Acid of Herpes Simplex Virus Subtypes 1 and 2 (1971) (344)
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors (1993) (344)
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes (1996) (339)
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. (1984) (333)
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus (1994) (329)
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1 (1990) (329)
Early events in Epstein-Barr virus infection of human B lymphocytes. (1991) (328)
Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. (1997) (311)
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein (1984) (298)
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. (2000) (297)
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. (1987) (286)
The structural basis for the recognition of diverse receptor sequences by TRAF2. (1999) (284)
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. (1994) (283)
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1 (1995) (278)
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE (1995) (267)
Role of NF-κB in Cell Survival and Transcription of Latent Membrane Protein 1-Expressing or Epstein-Barr Virus Latency III-Infected Cells (2004) (264)
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation (1991) (260)
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus (1986) (251)
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. (1996) (250)
Role of the TRAF Binding Site and NF-κB Activation in Epstein-Barr Virus Latent Membrane Protein 1-Induced Cell Gene Expression (1998) (249)
The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. (1997) (245)
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. (2008) (242)
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. (1991) (238)
Epstein–Barr virus latent genes (2015) (236)
Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. (2000) (232)
Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells (2011) (227)
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. (1996) (223)
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. (1999) (222)
Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation (1997) (219)
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. (1984) (217)
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. (1986) (215)
Genetic Analysis of Human Traits In Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines (2008) (215)
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa) (1996) (208)
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF‐κB activation (2011) (206)
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation (1991) (199)
Oncogenic Forms of NOTCH1 Lacking Either the Primary Binding Site for RBP-Jκ or Nuclear Localization Sequences Retain the Ability to Associate with RBP-Jκ and Activate Transcription* (1997) (195)
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. (1987) (191)
The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues (1995) (188)
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1 (1990) (186)
Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth (2011) (186)
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation (1997) (185)
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins (1989) (182)
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. (1983) (182)
Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II (2002) (179)
Two related Epstein-Barr virus membrane proteins are encoded by separate genes (1989) (178)
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa (1995) (175)
The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. (1997) (174)
Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. (2001) (174)
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies (1983) (172)
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase (1991) (168)
Interpreting cancer genomes using systematic host perturbations by tumour virus proteins (2012) (167)
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes (1993) (166)
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. (1980) (166)
Virus and Cell RNAs Expressed during Epstein-Barr Virus Replication (2006) (163)
Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein. (1996) (163)
Genetic Relatedness of Type 1 and Type 2 Herpes Simplex Viruses (1972) (162)
The Epstein-Barr Virus Oncoprotein Latent Membrane Protein 1 Engages the Tumor Necrosis Factor Receptor-Associated Proteins TRADD and Receptor-Interacting Protein (RIP) but Does Not Induce Apoptosis or Require RIP for NF-κB Activation (1999) (161)
Epstein–Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKKα-dependent noncanonical NF-κB activation (2003) (159)
Epstein–Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ (1998) (159)
Lymphotoxin-β receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κB (1997) (159)
Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry (2018) (157)
Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. (1984) (156)
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative (1980) (155)
LMP1 TRAFficking activates growth and survival pathways. (2007) (153)
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases (1992) (153)
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. (1991) (152)
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line (1980) (151)
Epstein-Barr Virus-Induced Changes in B-Lymphocyte Gene Expression (2002) (151)
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro (1992) (149)
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. (1983) (146)
Epstein–Barr virus latent membrane protein 1 activation of NF-κB through IRAK1 and TRAF6 (2003) (142)
Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes (1988) (141)
Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. (1990) (140)
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication (1991) (137)
A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. (1998) (137)
Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells (2015) (135)
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells (1981) (132)
Epstein-Barr virus oncoprotein super-enhancers control B cell growth. (2015) (132)
An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator (1991) (131)
The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein (1995) (129)
The NF-κB genomic landscape in lymphoblastoid B cells. (2014) (128)
An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes (1987) (128)
The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro (1993) (128)
Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110 (1990) (126)
The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. (1995) (123)
Long internal direct repeat in Epstein-Barr virus DNA (1982) (123)
EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes (1996) (122)
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts (1988) (121)
Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus (1976) (121)
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes (1987) (120)
Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene (1985) (120)
Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element (1991) (118)
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. (2006) (118)
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP (1988) (118)
Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression (2011) (115)
Epstein-Barr Virus BHRF1 Micro- and Stable RNAs during Latency III and after Induction of Replication (2007) (114)
Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB (1987) (114)
Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilodalton actin-bundling protein (1994) (114)
The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential (1992) (113)
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. (1992) (113)
A second nuclear protein is encoded by Epstein-Barr virus in latent infection. (1985) (111)
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B (1993) (109)
Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. (1983) (108)
Viral Perturbations of Host Networks Reflect Disease Etiology (2012) (106)
Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. (1994) (105)
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. (1990) (105)
Mediation of Epstein–Barr virus EBNA‐LP transcriptional coactivation by Sp100 (2005) (104)
Epstein-Barr Virus Nuclear Antigen 3C Putative Repression Domain Mediates Coactivation of the LMP1 Promoter with EBNA-2 (2002) (104)
DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness (1975) (101)
Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression (1991) (100)
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells (1982) (99)
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1 (1996) (99)
Genome-wide siRNA screen for mediators of NF-κB activation (2012) (98)
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. (1981) (97)
The Residues between the Two Transformation Effector Sites of Epstein-Barr Virus Latent Membrane Protein 1 Are Not Critical for B-Lymphocyte Growth Transformation (1999) (93)
Epstein-Barr virus recombinants with specifically mutated BCRF1 genes (1993) (92)
A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes (1988) (92)
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle (1992) (91)
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. (1986) (88)
Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus (1976) (88)
An Epstein-Barr Virus That Expresses Only the First 231 LMP1 Amino Acids Efficiently Initiates Primary B-Lymphocyte Growth Transformation (1999) (87)
Characterization of an Epstein-Barr virus receptor on human epithelial cells (1992) (87)
Complexity of EBV homologous DNA in continuous lymphoblastoid cell lines. (1976) (86)
Size and Composition of Marek's Disease Virus Deoxyribonucleic Acid (1971) (86)
An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200) (1984) (84)
Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. (2004) (83)
Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. (1994) (82)
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus (1978) (82)
Varicella-zoster virus as a live vector for the expression of foreign genes. (1987) (82)
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. (1996) (81)
Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes (1990) (81)
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA (1979) (80)
Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. (2005) (80)
Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A (2013) (79)
An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro (1994) (79)
Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation (1994) (79)
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections (1982) (78)
RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. (2006) (78)
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells (1986) (77)
Identification of the Epstein-Barr virus gp85 gene (1988) (77)
Expression of Epstein-Barr Virus Nuclear Antigen 1 Is Associated with Enhanced Expression of CD25 in the Hodgkin Cell Line L428 (1999) (76)
Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling (2003) (75)
The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. (2017) (75)
Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus. (1987) (75)
Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. (1990) (74)
Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection. (1982) (74)
Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus (1976) (72)
Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB. (2006) (72)
Epstein-Barr virus recombinants from overlapping cosmid fragments (1993) (72)
The biology and chemistry of Epstein-Barr virus. (1982) (72)
EBNA3A Association with RBP-Jκ Down-Regulates c-myc and Epstein-Barr Virus-Transformed Lymphoblast Growth (2003) (71)
Role of Cellular Tumor Necrosis Factor Receptor-Associated Factors in NF-κB Activation and Lymphocyte Transformation by Herpesvirus Saimiri STP (1999) (70)
Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation (2016) (69)
A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. (1985) (68)
A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells (2017) (67)
Epstein-Barr Virus Nuclear Protein EBNA3A Is Critical for Maintaining Lymphoblastoid Cell Line Growth (2003) (67)
Epstein-Barr virus DNA XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion (1982) (66)
A Vibrio parahaemolyticus T3SS effector mediates pathogenesis by independently enabling intestinal colonization and inhibiting TAK1 activation. (2013) (66)
DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration (1979) (66)
Epstein–Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth (2001) (65)
Nonmuscle myosin heavy chain IIA mediates Epstein–Barr virus infection of nasopharyngeal epithelial cells (2015) (64)
Epstein-Barr virus vectors for gene delivery to B lymphocytes. (1996) (64)
EBNA-LP Associates with Cellular Proteins Including DNA-PK and HA95 (2001) (64)
The Epstein-Barr Virus Latent Membrane Protein 1 Putative Janus Kinase 3 (JAK3) Binding Domain Does Not Mediate JAK3 Association or Activation in B-Lymphoma or Lymphoblastoid Cell Lines (2002) (64)
Epstein-Barr virus--increasing evidence of a link to carcinoma. (1995) (63)
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus (1978) (63)
The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B. (2000) (62)
Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection (1992) (62)
Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. (1997) (61)
cis-acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site (1990) (61)
EBNA3C Coactivation with EBNA2 Requires a SUMO Homology Domain (2004) (60)
Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes (1992) (60)
EBNA-3B- and EBNA-3C-Regulated Cellular Genes in Epstein-Barr Virus-Immortalized Lymphoblastoid Cell Lines (2006) (59)
Effects of virally expressed interleukin-10 on vaccinia virus infection in mice (1993) (58)
Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines (1989) (58)
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. (1998) (58)
Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells (1987) (58)
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells (1992) (58)
Repeat array in Epstein-Barr virus DNA is related to cell DNA sequences interspersed on human chromosomes. (1982) (57)
The Epstein-Barr virus nuclear antigen leader protein associates with hsp72/hsc73 (1995) (56)
Epstein–Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2 (2013) (54)
Electroporation of antibodies, DNA, and other macromolecules into cells: a highly efficient method. (2000) (54)
Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth (2009) (52)
Comparative studies of Epstein‐barr virus strains from Ghana and the United States (1976) (51)
Epstein–Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines (2010) (49)
A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) is induced by the EBV oncogene LMP1 (1994) (49)
Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs (1995) (49)
Identification and characterization of a cellular protein that cross-reacts with the Epstein-Barr virus nuclear antigen (1984) (48)
IRF7 activation by Epstein–Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3 (2008) (48)
Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing (2016) (47)
IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-κB activation (2006) (46)
Identification and nucleotide sequences of two similar tandem direct repeats in Epstein-Barr virus DNA (1982) (46)
IκB kinase β phosphorylates Dok1 serines in response to TNF, IL-1, or γ radiation (2004) (46)
Protein Kinase A Associates with HA95 and Affects Transcriptional Coactivation by Epstein-Barr Virus Nuclear Proteins (2002) (44)
Epstein–Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes (2014) (44)
Epstein-Barr virus RNA in Burkitt tumor tissue (1979) (44)
Bronchial brushing in the diagnosis of pulmonary disease in patients at risk for opportunistic infection. (1974) (43)
Herpesvirus papio DNA is similar in organization to Epstein-Barr virus DNA (1981) (43)
Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A (2015) (43)
EPSTEIN-BARR VIRUS TYPE 1 (EBV-1) AND 2 (EBV-2) DIFFER IN THEIR EBNA-3A, EBNA-3B, AND EBNA-3C GENES (1990) (43)
The Epstein-Barr virus-induced Ca2+/calmodulin-dependent kinase type IV/Gr promotes a Ca(2+)-dependent switch from latency to viral replication (1997) (42)
Colinearity between the DNAs of Epstein-Barr virus and herpesvirus papio (1981) (42)
Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat (1985) (42)
RNA encoded by the IR1-U2 region of Epstein-Barr virus DNA in latently infected, growth-transformed cells (1983) (42)
Epstein–Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4 (2006) (42)
Epstein-Barr Virus Nuclear Antigen 1 Does Not Cause Lymphoma in C57BL/6J Mice (2008) (42)
Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation. (2004) (42)
Epstein-Barr virus-specific RNA. I. Analysis of viral RNA in cellular extracts and in the polyribosomal fraction of permissive and nonpermissive lymphoblastoid cell lines (1976) (41)
The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains (1994) (41)
A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes (1988) (40)
Epstein-Barr Virus Nuclear Protein 2 Has at Least Two N-Terminal Domains That Mediate Self-Association (2001) (40)
EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding (2011) (40)
Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. (2005) (40)
Epstein-Barr Virus Nuclear Protein 3A Domains Essential for Growth of Lymphoblasts: Transcriptional Regulation through RBP-Jκ/CBF1 Is Critical (2005) (39)
Epstein-Barr Virus-Specific RNA III. Mapping of DNA Encoding Viral RNA in Restringent Infection (1979) (39)
Nucleolin is important for Epstein–Barr virus nuclear antigen 1-mediated episome binding, maintenance, and transcription (2013) (39)
Epstein-Barr virus RNA. VI. Viral RNA in restringently and abortively infected Raji cells (1981) (37)
Canonical NF-κB Activation Is Essential for Epstein-Barr Virus Latent Membrane Protein 1 TES2/CTAR2 Gene Regulation (2011) (37)
Effects of the NIK aly Mutation on NF-κB Activation by the Epstein-Barr Virus Latent Infection Membrane Protein, Lymphotoxin β Receptor, and CD40* (2001) (37)
Aseptic meningitis in association with herpes progenitalis. (1971) (36)
U 2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2 ( herpesvirus / nuclear antigens / sequence diversity / growth transformation / latency ) (36)
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. (1991) (36)
Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin (1989) (35)
Roscovitine Inhibits EBNA1 Serine 393 Phosphorylation, Nuclear Localization, Transcription, and Episome Maintenance (2011) (35)
Mouse model of Epstein–Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease (2017) (35)
Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells. (1991) (35)
The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation (1996) (34)
Erratum: Early events in Epstein-Barr virus infection of human B lymphocytes (Virology (1991) 181 (595-608)) (1991) (34)
Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes (1994) (33)
Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. (1994) (32)
Homology between Burkitt herpes viral DNA and DNA in continuous lymphoblastoid cells from patients with infectious mononucleosis. (1974) (32)
Epstein-Barr Virus Nuclear Protein 3C Domains Necessary for Lymphoblastoid Cell Growth: Interaction with RBP-Jκ Regulates TCL1 (2009) (32)
IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. (2004) (32)
The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat (1990) (32)
Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. (1994) (32)
Nasopharyngeal carcinoma super-enhancer–driven ETV6 correlates with prognosis (2017) (32)
The Nuclear Chaperone Nucleophosmin Escorts an Epstein-Barr Virus Nuclear Antigen to Establish Transcriptional Cascades for Latent Infection in Human B Cells (2012) (32)
DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group (1982) (31)
Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with EBNA2. (2007) (30)
VARIATIONS AMONG ISOLATES OF EPSTEIN‐BARR VIRUS * (1980) (30)
Identification, cloning and characterization of a novel nuclear protein, HA95, homologous to A‐kinase anchoring protein 95 * (2000) (30)
LMP1 Transmembrane Domain 1 and 2 (TM1-2) FWLY Mediates Intermolecular Interactions with TM3-6 To Activate NF-κB (2006) (28)
Four EBNA2 Domains Are Important for EBNALP Coactivation (2004) (28)
Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome. (1998) (26)
Role of Ca2+/Calmodulin-Dependent Kinase II–IRAK1 Interaction in LMP1-Induced NF-κB Activation (2013) (26)
Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical. (2005) (25)
Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes (2015) (25)
A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame. (1995) (24)
Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. (1989) (24)
Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. (2014) (24)
Modulation of Apoptosis by Herpesviruses (1998) (23)
Residues 231 to 280 of the Epstein-Barr Virus Nuclear Protein 2 Are Not Essential for Primary B-Lymphocyte Growth Transformation (1998) (23)
The PP4R1 subunit of protein phosphatase PP4 targets TRAF2 and TRAF6 to mediate inhibition of NF-κB activation. (2014) (23)
Epstein-barr virus-specific RNA. II. Analysis of polyadenylated viral RNA in restringent, abortive, and prooductive infections (1977) (23)
Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants (1992) (23)
Cephalexin-related nephropathy. (1975) (22)
IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation. (2006) (22)
Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation (2012) (21)
Epstein-Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. (2011) (21)
Expression of Epstein-Barr virus (EBV) DNA and cloned DNA fragments in human lymphocytes following Sendai virus envelope-mediated gene transfer. (1984) (21)
cis-Acting Effects on RNA Processing and Drosha Cleavage Prevent Epstein-Barr Virus Latency III BHRF1 Expression (2011) (21)
Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization. (2012) (20)
Ribosome Protein L4 is essential for Epstein–Barr Virus Nuclear Antigen 1 function (2016) (18)
NF-κB Inhibition in EBV-Transformed Lymphoblastoid Cell Lines (2002) (18)
Herpes simplex virus expressing Epstein-Barr virus nuclear antigen 1. (1986) (18)
A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant (1992) (18)
Epstein – Barr virus nuclear protein 2 interacts with p 300 , CBP , and PCAF histone acetyltransferases in activation of the LMP 1 promoter (1999) (18)
Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: a method useful for analysis of genes essential for transformation (1993) (17)
Epstein-Barr virus: structure of the viral DNA and analysis of viral RNA in infected cells. (1979) (17)
Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40. (2001) (16)
Epstein – Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NFk B through a pathway that includes the NFk B-inducing kinase and the I k B kinases IKK a and IKK b (1998) (15)
Biochemistry of Epstein—Barr Virus (1982) (15)
Modulation of Epstein-Barr virus nuclear antigen 2-dependent transcription by protein arginine methyltransferase 5. (2013) (15)
Epstein-Barr latent membrane protein 1 transformation site 2 activates NF-κB in the absence of NF-κB essential modifier residues 133–224 or 373–419 (2010) (14)
Marek's disease herpes virus: a cytomegalovirus. (1969) (14)
Constitutive CD40 signaling phenocopies the transforming function of the Epstein-Barr virus oncoprotein LMP1 in vitro. (2007) (14)
Herpes Simplex and Epstein-Barr Viruses in Human Cells and Tissues: A Study in Contrasts (1975) (14)
Epstein-Barr Virus-Specific RNA II . Analysis of Polyadenylated Viral RNA in Restringent , Abortive , and Productive Infections (13)
Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection (1986) (13)
Intracellular forms of human NOTCH1 interact at distinctly different levels with RBP-Jkappa in human B and T cells (2000) (13)
Epstein-Barr virus DNA. X. Direct repeat within the internal direct repeat of Epstein-Barr virus DNA (1981) (12)
Recognition of EBV plasma membrane protein expressed on murine cells after gene transfer. (1987) (11)
Hypertrophic osteoarthropathy with arthritis and synovial calcification in a patient with alcoholic cirrhosis. (1969) (11)
Persistence and Expression of the Epstein-Barr Virus Genome in Latent Infection and Growth Transformation of Lymphocytes (1985) (11)
Antibiotic treatment of oral anaerobic infections. (1975) (11)
Latent Membrane Protein 1 Is Dispensable for Epstein-Barr Virus Replication in Human Embryonic Kidney 293 cells (2011) (11)
Biochemistry of latent Epstein-Barr virus infection and associated cell growth transformation. (1985) (10)
Lymphotoxin-b receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kB (1997) (9)
Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry (2018) (9)
IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p 65 / RelA serine 536 phosphorylation and NF-B activation (2006) (9)
Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition (LMI) in infectious mononucleosis (IM). I. Kinetics and response to a membrane protein on EBV-transformed cells. (1986) (8)
Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells (1991) (7)
Why commonplace encounters turn to fatal attraction (1998) (7)
The Clinical Research Forum and Association of American Physicians disagree with criticism of the NIH Roadmap. (2006) (7)
Hsp 72 upregulates Epstein-Barr virus EBNALP coactivation with EBNA 2 (2007) (7)
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybrids. (1981) (7)
Expression of Epstein-Barr Virus Nuclear Antigen 1 Is Associated with Enhanced Expression of CD 25 in the Hodgkin Cell Line L 428 (1998) (6)
Epstein-Barr VirusLatentInfection MembraneProtein Increases Vimentin Expression inHumanB-Cell Lines (1989) (6)
THE DNA OF EPSTEIN-BARR VIRUS FRAGMENTS PRODUCED BY RESTRICTION ENZYMES: HOMOLOGOUS DNA AND RNA IN LYMPHOBLASTOID CELLS (1976) (6)
Author Correction: Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry (2018) (6)
EBNA-3 Band EBNA-3 C-Regulated Cellular Genes in Epstein-Barr Virus-Immortalized Lymphoblastoid Cell Lines (2006) (5)
Epstein-barr virus (2013) (5)
Making the Soldier Decisive on Future Battlefields (2013) (5)
Altered growth phenotype of a Burkitt's lymphoma line following the introduction and stable expression of the EBNA 2A gene. (1988) (4)
Analysis of the DNA OF Epstein-Barr viruses and transcriptional products in transformed cells. (1975) (4)
Molecular basis for Epstein-Barr virus induced pathogenesis and disease (1991) (4)
10 Oncogenesis by Herpesviruses (1989) (3)
Expression and Analysis of EBV gp350 in the Yeast Saccharomyces Cerevisiae (1987) (3)
Editorial: Epstein-Barr Virus: New Insights (1995) (3)
Complexity of EBV homologous DNA in continous lymphoblastoid cell lines. (1976) (3)
Epstein–Barr Virus Latent Infection Nuclear Proteins: Genome Maintenance and Regulation of Lymphocyte Cell Growth and Survival (2009) (3)
NF-kappaB inhibition in EBV-transformed lymphoblastoid cell lines. (2002) (3)
Erratum: A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes (Journal of Virology 70:2 (1145)) (1996) (3)
The Epstein – Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NFk B (1997) (2)
Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing (2011) (2)
Epstein-Barr Virus Nuclear Antigen 1 Does Not Cause Lymphoma in C 57 BL / 6 J Mice (2008) (2)
Epstein-Barr Virus(EBV)Recombinants: UseofPositive Selection Markers ToRescueMutants inEBV-Negative B-LymphomaCells (1991) (2)
Meeting Report Fourth International Symposium on Nasopharyngeal Carcinoma Application of Field and Laboratory Studies to the Control of NPC1'2'3 (2006) (2)
associated with human cancer The dynamic DNA methylomes of double-stranded DNA viruses Material Supplemental (2009) (1)
Epstein-Barr virus types 1 and 2 have nearly identical LMP1 transforming genes (2007) (1)
Supplementary Material 23 (2012) (1)
Epstein-Barr virus: new insights. (1995) (1)
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. (1997) (1)
Actin-Bundling Protein (2007) (1)
Epstein-Barr virus types 1 and 2 have nearly identical LMP1 transforming genes (2007) (1)
Mapping of putative transforming sequences of EBV DNA. (1978) (1)
Viral Pathogenesis of AIDS Related Malignancies: S2 (1997) (0)
Canonical NF- (cid:1) B Activation Is Essential for Epstein-Barr Virus Latent Membrane Protein 1 TES2/CTAR2 Gene Regulation (cid:1) † (2011) (0)
Germinal center reaction (WS-031) Chairpersons: Nobuo Sakaguchi, Garnett Kelsoe (2010) (0)
Mechanisms of gene regulation and transformation by epstein barr virus (2007) (0)
I¿B kinase ß phosphorylates Dok1 serines in response to TNF, IL-1, or ¿ small gamma radiation (2004) (0)
B cells following recombinant vaccinia infection andtheir recognition byhumancytotoxic T cells (1991) (0)
Management of infectious diseases: Introduction. (1976) (0)
Supplementary Material 12 (2015) (0)
TheEpstein-Barr virus nuclear antigen 2transactivator isdirected toresponse elements bytheJKcrecombination signal binding protein (1994) (0)
The Structural Basis for the Recognition of Diverse Receptor Sequences by TRAF 2 signaling complex (1999) (0)
EPSTEIN‐BARR VIRUS USURPS TUMOR NECROSIS FACTOR AND NOTCH RECEPTOR PATHWAYS TO CAUSE LYMPHOCYTE PROLIFERATION AND SURVIVAL.: ABSTRACT S14 (2000) (0)
Cancer Science: The official journal of the Japanese Cancer Association (2014) (0)
Epstein-Barr Virus Transformation of B Lymphocytes: Molecular Pathogenesis (1989) (0)
Epstein-Barr VirusRecombinants withSpecifically Mutated BCRF1Genes (1993) (0)
NOTES Effect of Mycophenolic Acid on Epstein-Barr Virus Infection of Human B Lymphocytes (0)
CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE TRAF DOMAIN OF HUMAN TRAF2 AND AN LMP1 BINDING PEPTIDE (2000) (0)
Issue Information (2022) (0)
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 17-RESIDUE CD40 PEPTIDE (2000) (0)
, Protein 1 TES 2 / CTAR 2 Gene Regulation Epstein-Barr Virus Latent Membrane B Activation Is Essential for κ (2011) (0)
Abstracts of papers presented at the fourth Cold Spring Harbor Meeting on Herpesviruses, August 28-September 2, 1979 (1979) (0)
Epstein-Barr Virus Nuclear Antigen 1 Does Not Cause Lymphoma in C57BL/6J Mice (cid:1) (2008) (0)
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A M4-1BB PEPTIDE (2000) (0)
Deoxyribonucleic Acid of Herpes Simplex Virus (2003) (0)
Deoxyribonucleic Acid Marek's Disease Virus Size and Composition of (2013) (0)
Author Correction: Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry (2018) (0)
EBNA-2 Transactivation of CD23 (1991) (0)
Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
Interaction of EBV Genes with Human Epithelial Cells (1991) (0)
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 5-RESIDUE CD40 PEPTIDE (2000) (0)
Epstein-Barr Virus Nuclear Protein 3A Domains Essential for Growth of Lymphoblasts: Transcriptional Regulation through RBP-J (cid:2) /CBF1 Is Critical (2005) (0)
EBNA2 Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with (2013) (0)
Repeat array inEpstein-Barr virus DNAisrelated tocell DNA sequences interspersed onhumanchromosomes (1982) (0)
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 (TRAF2) IN COMPLEX WITH A HUMAN OX40 PEPTIDE (2000) (0)
lymphocytes in vitro. deletion that includes BARF0 transforms B An Epstein-Barr virus with a 58-kilobase-pair (2013) (0)
Expression of the Major Envelope Glycoprotein gp350/220 of Epstein-Barr Virus by a Recombinant Varicella Zoster Virus (1987) (0)
Characterization of Two Forms of the 72,000 MW EBNA and a Cross-Reacting Cellular Protein (1985) (0)
Issue Information (2022) (0)
Negotiating parental requests for medication. (2007) (0)
Genetic Mapping of Antibiotic Resistance in Markers Bacillus subtilis* (0)
Homology Between Burkitt HerpFes Viral DNA and DNA in Continuous Lymphoblastoid Cells from Patients with Infectious Mononucleosis (DNA. DNA reassociation/Epstein-Barr virus/DNA/matching base pairs) (2016) (0)
EBNA-2 Transactivation of LMP1 (1991) (0)
Supplementary Material 18 (2014) (0)
Supplementary Material 16 (2012) (0)
Phenotypes ofEpstein-Barr VirusLMP1 Deletion Mutants Indicate Transmembrane andAmino-Terminal Cytoplasmic DomainsNecessary forEffects inB-LymphomaCells (1992) (0)
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A HUMAN CD30 PEPTIDE (2003) (0)
Issue Information (2018) (0)
Chromatin Immunoprecipitation (ChIP), Streptavidin and ATP-agarose Mediated Pull-down Analyses (2013) (0)
Genome-Wide Analysis Reveals Conserved and Divergent Features of Notch1/RBPJ Binding in Human and Murine T Lymphoblastic Leukemia Cells (2011) (0)
Cell Reports Resource The NFk B Genomic Landscape in Lymphoblastoid B Cells (2014) (0)
Role of Ca 2 (cid:2) /Calmodulin-Dependent Kinase II–IRAK1 Interaction in LMP1-Induced NF- (cid:2) B Activation (2013) (0)
Cell Growth Transformation by Epstein Barr Virus (1991) (0)
418 rIL-4 and EBV induce germ-line and mature Cϵ transcripts in human B cells (1991) (0)
The Epstein-Barr Virus Oncoprotein Latent Membrane Protein 1 Engages the Tumor Necrosis Factor Receptor-Associated Proteins TRADD and Receptor-Interacting Protein (RIP) but Does Not Induce Apoptosis or Require RIP for NF- k B Activation (1999) (0)

This paper list is powered by the following services:

Other Resources About Elliott D. Kieff

en.wikipedia.org

What Schools Are Affiliated With Elliott D. Kieff?

Elliott D. Kieff is affiliated with the following schools:

Elliott D. Kieff's Academic­Influence.com Rankings

Why Is Elliott D. Kieff Influential?

Elliott D. Kieff's Published Works

Published Works

Other Resources About Elliott D. Kieff

What Schools Are Affiliated With Elliott D. Kieff?

Elliott D. Kieff's AcademicInfluence.com Rankings